Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-17T15:47:30.198Z Has data issue: false hasContentIssue false
  • English
  • Français

Off-label psychopharmacological interventions for autism spectrum disorders: strategic pathways for clinicians

Published online by Cambridge University Press:  04 August 2023

Nihit Gupta Open the ORCID record for Nihit Gupta [Opens in a new window]  and
Mayank Gupta Open the ORCID record for Mayank Gupta [Opens in a new window]
Nihit Gupta
Affiliation:
Dayton Children’s Hospital, Dayton, OH, USA
Mayank Gupta*
Affiliation:
Southwood Psychiatric Hospital, Pittsburgh, PA, USA
*
Corresponding author: Mayank Gupta; Email: mayank6nov@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

The prevalence of autism spectrum disorder (ASD) continues to see a trend upward with a noticeable increase to 1 in 36 children less than 8 years of age in the recent MMWR. There are many factors linked to the substantially increased burden of seeking mental health services, and clinically these individuals are likely to present for impairments associated with co-occurring conditions. The advances in cutting-edge research and the understanding of co-occurring conditions in addition to psychosocial interventions have provided a window of opportunity for psychopharmacological interventions given the limited availability of therapeutics for core symptomatology. The off-label psychopharmacological treatments for these co-occurring conditions are central to clinical practice. However, the scattered evidence remains an impediment for practitioners to systematically utilize these options. The review collates the crucial scientific literature to provide stepwise treatment alternatives for individuals with ASD; with an aim to lead practitioners in making informed and shared decisions. There are many questions about the safety and tolerability of off-label medications; however, it is considered the best practice to utilize the available empirical data in providing psychoeducation for patients, families, and caregivers. The review also covers experimental medications and theoretical underpinnings to enhance further experimental studies. In summary, amidst the growing clinical needs for individuals with ASD and the lack of approved clinical treatments, the review addresses these gaps with a practical guide to appraise the risk and benefits of off-label medications.

Keywords

autismoff-labelcomorbiditySSRIASDpsychopharmacologyco-occuring disorders
Type
Review
Information
CNS Spectrums , Volume 29 , Issue 1 , February 2024 , pp. 10 - 25
Copyright
© The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Maenner, MJ. Prevalence and characteristics of autism spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 Sites, United States. MMWR Surveill Summ. 2020;2023:72. doi:10.15585/mmwr.ss7202a1Google Scholar
Goel, R, Hong, JS, Findling, RL, Ji, NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry Abingdon Engl. 2018;30(1):78–95. doi:10.1080/09540261.2018.1458706CrossRefGoogle ScholarPubMed
Gosling, CJ, Cartigny, A, Mellier, BC, Solanes, A, Radua, J, Delorme, R. Efficacy of psychosocial interventions for autism spectrum disorder: an umbrella review. Mol Psychiatry. 2022;27(9):3647–3656. doi:10.1038/s41380-022-01670-zCrossRefGoogle ScholarPubMed
Subramanyam, AA, Mukherjee, A, Dave, M, Chavda, K. Clinical practice guidelines for autism spectrum disorders. Indian J Psychiatry. 2019;61(Suppl 2):254. doi:10.4103/psychiatry.IndianJPsychiatry_542_18CrossRefGoogle ScholarPubMed
Blankenship, K, Erickson, CA, Stigler, KA, Posey, DJ, McDougle, CJ. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatr Health. 2010;4(4):375–381.CrossRefGoogle ScholarPubMed
Simonoff, E, Pickles, A, Charman, T, Chandler, S, Loucas, T, Baird, G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–929. doi:10.1097/CHI.0b013e318179964fCrossRefGoogle Scholar
Bonati, M, Jacqz-Aigrain, E, Choonara, I. Licensed medicines, off-label use or evidence-based. Which is most important? Arch Dis Child. 2017;102(1):53–54. doi:10.1136/archdischild-2016-311527CrossRefGoogle ScholarPubMed
Syed, SA, Dixson, BA, Constantino, E, Regan, J. The law and practice of off-label prescribing and physician promotion. J Am Acad Psychiatry Law. 2021;49(1):53–59. doi:10.29158/JAAPL.200049-20Google ScholarPubMed
Braüner, JV, Johansen, LM, Roesbjerg, T, Pagsberg, AK. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol. 2016;36(5):500–507. doi:10.1097/JCP.0000000000000559CrossRefGoogle ScholarPubMed
Lopez-Leon, S, Lopez-Gomez, MI, Warner, B, Ruiter-Lopez, L. Psychotropic medication in children and adolescents in the United States in the year 2004 vs 2014. Daru J Fac Pharm Tehran Univ Med Sci. 2018;26(1):5–10. doi:10.1007/s40199-018-0204-6CrossRefGoogle ScholarPubMed
Madden, JM, Lakoma, MD, Lynch, FL, et al. Psychotropic medication use among insured children with autism spectrum disorder. J Autism Dev Disord. 2017;47(1):144–154. doi:10.1007/s10803-016-2946-7CrossRefGoogle ScholarPubMed
Bejarano-Martín, Á, Canal-Bedia, R, Magán-Maganto, M, et al. Efficacy of focused social and communication intervention practices for young children with autism spectrum disorder: A meta-analysis. Early Child Res Q. 2020;51:430–445. doi:10.1016/j.ecresq.2020.01.004CrossRefGoogle Scholar
Williams, K, Brignell, A, Randall, M, Silove, N, Hazell, P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;(8):CD004677. doi:10.1002/14651858.CD004677.pub3Google ScholarPubMed
Zhou, MS, Nasir, M, Farhat, LC, Kook, M, Artukoglu, BB, Bloch, MH. Meta-analysis: pharmacologic treatment of restricted and repetitive behaviors in autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2021;60(1):35–45. doi:10.1016/j.jaac.2020.03.007CrossRefGoogle ScholarPubMed
McDougle, CJ, Scahill, L, Aman, MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142–1148. doi:10.1176/appi.ajp.162.6.1142CrossRefGoogle Scholar
Canitano, R, Scandurra, V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat. 2008;4(4):723–730. doi:10.2147/ndt.s1450CrossRefGoogle ScholarPubMed
Ooi, YP, Weng, SJ, Kossowsky, J, Gerger, H, Sung, M. Oxytocin and autism spectrum disorders: a systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2017;50(1):5–13. doi:10.1055/s-0042-109400Google ScholarPubMed
Handen, BL, Johnson, CR, Lubetsky, M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245–255. doi:10.1023/A:1005548619694CrossRefGoogle ScholarPubMed
Quintana, H, Birmaher, B, Stedge, D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25(3):283–294. doi:10.1007/BF02179289CrossRefGoogle ScholarPubMed
Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266–1274. doi:10.1001/archpsyc.62.11.1266CrossRefGoogle Scholar
Sturman, N, Deckx, L, van Driel, ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev. 2017;11:CD011144. doi:10.1002/14651858.CD011144.pub2Google ScholarPubMed
Pearson, DA, Santos, CW, Aman, MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013;23(5):337–351. doi:10.1089/cap.2012.0096CrossRefGoogle ScholarPubMed
Kim, SJ, Shonka, S, French, WP, Strickland, J, Miller, L, Stein, MA. Dose-response effects of long-acting liquid methylphenidate in children with attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): a pilot study. J Autism Dev Disord. 2017;47(8):2307–2313. doi:10.1007/s10803-017-3125-1CrossRefGoogle ScholarPubMed
Pearson, DA, Santos, CW, Aman, MG, et al. Effects of extended-release methylphenidate treatment on cognitive task performance in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30(7):414–426. doi:10.1089/cap.2020.0004CrossRefGoogle ScholarPubMed
Joshi, G, Wilens, T, Firmin, ES, Hoskova, B, Biederman, J. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: a systematic review of the literature. J Psychopharmacol Oxf Engl. 2021;35(3):203–210. doi:10.1177/0269881120972336CrossRefGoogle ScholarPubMed
Ghanizadeh, A, Molla, M, Olango, GJ. The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review. Neuropsychiatr Dis Treat. 2019;15:1547. doi:10.2147/NDT.S194022CrossRefGoogle ScholarPubMed
Troost, PW, Steenhuis, MP, Tuynman-Qua, HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16(5):611–619. doi:10.1089/cap.2006.16.611CrossRefGoogle ScholarPubMed
Posey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006). Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of child and adolescent psychopharmacology, 16(5), 599–610. https://doi.org/10.1089/cap.2006.16.599.CrossRefGoogle ScholarPubMed
Harfterkamp, M, van de Loo-Neus, G, Minderaa, RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(7):733–741. doi:10.1016/j.jaac.2012.04.011CrossRefGoogle ScholarPubMed
van der Meer, JMJ, Harfterkamp, M, van de Loo-Neus, G, et al. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms. J Clin Psychopharmacol. 2013;33(6):824–827. doi:10.1097/JCP.0b013e31829c764fCrossRefGoogle ScholarPubMed
Harfterkamp, M, Buitelaar, JK, Minderaa, RB, van de Loo-Neus, G, van der Gaag, RJ, Hoekstra, PJ. Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. J Child Adolesc Psychopharmacol. 2014;24(9):481–485. doi:10.1089/cap.2014.0026CrossRefGoogle ScholarPubMed
Harfterkamp, M, Buitelaar, JK, Minderaa, RB, van de Loo-Neus, G, van der Gaag, RJ, Hoekstra, PJ. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol. 2013;23(3):194–199. doi:10.1089/cap.2012.0012CrossRefGoogle ScholarPubMed
Handen, BL, Aman, MG, Arnold, LE, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):905–915. doi:10.1016/j.jaac.2015.08.013CrossRefGoogle ScholarPubMed
Smith, T, Aman, MG, Arnold, LE, et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. J Am Acad Child Adolesc Psychiatry. 2016;55(10):868–876.e2. doi:10.1016/j.jaac.2016.06.015CrossRefGoogle ScholarPubMed
Arnold, LE, Ober, N, Aman, MG, et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. J Child Adolesc Psychopharmacol. 2018;28(5):322–330. doi:10.1089/cap.2017.0134CrossRefGoogle Scholar
Conners, CK, Casat, CD, Gualtieri, CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35(10):1314–1321. doi:10.1097/00004583-199610000-00018CrossRefGoogle ScholarPubMed
Leverich, GS, Altshuler, LL, Frye, MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163(2):232–239. doi:10.1176/appi.ajp.163.2.232CrossRefGoogle ScholarPubMed
Post, RM, Altshuler, LL, Frye, MA, et al. New findings from the bipolar collaborative network: clinical implications for therapeutics. Curr Psychiatry Rep. 2006;8(6):489–497. doi:10.1007/s11920-006-0056-5CrossRefGoogle ScholarPubMed
Johnson, KP, Malow, BA. Sleep in children with autism spectrum disorders. Curr Treat Options Neurol. 2008;10(5):350–359. doi:10.1007/s11940-008-0038-5CrossRefGoogle ScholarPubMed
Banas, K, Sawchuk, B. Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: a systematic literature review. J Can Acad Child Adolesc Psychiatry 2020;29(2):110–120.Google ScholarPubMed
Scahill, L, McCracken, JT, King, BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 2015;172(12):1197–1206. doi:10.1176/appi.ajp.2015.15010055CrossRefGoogle ScholarPubMed
Politte, LC, Scahill, L, Figueroa, J, McCracken, JT, King, B, McDougle, CJ. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacol 2018;43(8):1772–1778. doi:10.1038/s41386-018-0039-3CrossRefGoogle ScholarPubMed
Lamberti, M, Siracusano, R, Italiano, D, et al. Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD: a pilot, open-label, randomized controlled study. Paediatr Drugs. 2016;18(4):319–329. doi:10.1007/s40272-016-0183-3CrossRefGoogle ScholarPubMed
McCracken, JT, McGough, J, Shah, B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321. doi:10.1056/NEJMoa013171CrossRefGoogle ScholarPubMed
Shea, S, Turgay, A, Carroll, A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634–e641. doi:10.1542/peds.2003-0264-FCrossRefGoogle ScholarPubMed
Aman, MG, Arnold, LE, McDougle, CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15(6):869–884. doi:10.1089/cap.2005.15.869CrossRefGoogle ScholarPubMed
Marcus, RN, Owen, R, Kamen, L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–1119. doi:10.1097/CHI.0b013e3181b76658CrossRefGoogle ScholarPubMed
Owen, R, Sikich, L, Marcus, RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–1540. doi:10.1542/peds.2008-3782CrossRefGoogle ScholarPubMed
Chen, JX, Su, YA, Bian, QT, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130–140. doi:10.1016/j.psyneuen.2015.04.011CrossRefGoogle ScholarPubMed
Chen, S, Barner, JC, Cho, E. Trends in off-label use of antipsychotic medications among Texas Medicaid children and adolescents from 2013 to 2016. J Manag Care Spec Pharm. 2021;27(8):1035–1045. doi:10.18553/jmcp.2021.27.8.1035Google ScholarPubMed
Loebel, A, Brams, M, Goldman, RS, et al. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord. 2016;46(4):1153–1163. doi:10.1007/s10803-015-2628-xCrossRefGoogle ScholarPubMed
Gupta, M, Hoover, G. Lurasidone an effective alternative for the treatment of irritability associated with autism spectrum disorder. Cureus. 2020;12(12):e12360. doi:10.7759/cureus.12360Google ScholarPubMed
Golubchik, P, Sever, J, Weizman, A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011;34(6):216–219. doi:10.1097/WNF.0b013e31823349acCrossRefGoogle ScholarPubMed
Malone, RP, Cater, J, Sheikh, RM, Choudhury, MS, Delaney, MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40(8):887–894. doi:10.1097/00004583-200108000-00009CrossRefGoogle ScholarPubMed
Potenza, MN, Holmes, JP, Kanes, SJ, McDougle, CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19(1):37–44. doi:10.1097/00004714-199902000-00008CrossRefGoogle ScholarPubMed
Hollander, E, Wasserman, S, Swanson, EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541–548. doi:10.1089/cap.2006.16.541CrossRefGoogle ScholarPubMed
Fido, A, Al-Saad, S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract 2008;17(5):415–418. doi:10.1159/000141508CrossRefGoogle ScholarPubMed
Lambrey, S, Falissard, B, Martin-Barrero, M, et al. Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol. 2010;20(1):79–80. doi:10.1089/cap.2009.0057CrossRefGoogle Scholar
Rothärmel, M, Szymoniak, F, Pollet, C, et al. Eleven years of clozapine experience in autism spectrum disorder: efficacy and tolerance. J Clin Psychopharmacol. 2018;38(6):577–581. doi:10.1097/JCP.0000000000000955CrossRefGoogle Scholar
Joshi, G, Biederman, J, Wozniak, J, et al. Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. CNS Neurosci Ther. 2012;18(1):28–33. doi:10.1111/j.1755-5949.2010.00219.xCrossRefGoogle ScholarPubMed
Stigler, KA, McDougle, CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. 2008;17(4):739–752, vii-viii. doi:10.1016/j.chc.2008.06.002CrossRefGoogle ScholarPubMed
Hollander, E, Dolgoff-Kaspar, R, Cartwright, C, Rawitt, R, Novotny, S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62(7):530–534. doi:10.4088/jcp.v62n07a05CrossRefGoogle ScholarPubMed
Hollander, E, Chaplin, W, Soorya, L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990–998. doi:10.1038/npp.2009.202CrossRefGoogle ScholarPubMed
Hollander, E, Soorya, L, Wasserman, S, Esposito, K, Chaplin, W, Anagnostou, E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9(2):209–213. doi:10.1017/S1461145705005791CrossRefGoogle ScholarPubMed
Hellings, JA, Weckbaugh, M, Nickel, EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(4):682–692. doi:10.1089/cap.2005.15.682CrossRefGoogle ScholarPubMed
Legido, A, Jethva, R, Goldenthal, MJ. Mitochondrial dysfunction in autism. Semin Pediatr Neurol. 2013;20(3):163–175. doi:10.1016/j.spen.2013.10.008CrossRefGoogle ScholarPubMed
Krähenbühl, S, Brandner, S, Kleinle, S, Liechti, S, Straumann, D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver. 2000;20(4):346–348. doi:10.1034/j.1600-0676.2000.020004346.xCrossRefGoogle ScholarPubMed
Rezaei, V, Mohammadi, MR, Ghanizadeh, A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1269–1272. doi:10.1016/j.pnpbp.2010.07.005CrossRefGoogle ScholarPubMed
Mintz, M, Hollenberg, E. Revisiting lithium: utility for behavioral stabilization in adolescents and adults with autism spectrum disorder. Psychopharmacol Bull. 2019;49(2):28–40.Google ScholarPubMed
Assistance Publique - Hôpitaux de Paris. Effect of Lithium in Patients with Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency): Pilot Study. clinicaltrials.gov; 2022; https://clinicaltrials.gov/ct2/show/NCT04623398. Accessed March 10, 2022.Google Scholar
Yuan, J, Song, J, Zhu, D, et al. Lithium treatment is safe in children with intellectual disability. Front Mol Neurosci. 2018;11:425. doi:10.3389/fnmol.2018.00425CrossRefGoogle ScholarPubMed
Belsito, KM, Law, PA, Kirk, KS, Landa, RJ, Zimmerman, AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31(2):175–181. doi:10.1023/a:1010799115457CrossRefGoogle ScholarPubMed
Guglielmo, R, Ioime, L, Grandinetti, P, Janiri, L. Managing disruptive and compulsive behaviors in adult with autistic disorder with gabapentin. J Clin Psychopharmacol. 2013;33(2):273–274. doi:10.1097/JCP.0b013e318285680cCrossRefGoogle ScholarPubMed
Robinson, AA, Malow, BA. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013;28(12):1618–1621. doi:10.1177/0883073812463069CrossRefGoogle ScholarPubMed
Rossignol, DA, Frye, RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53(9):783–792. doi:10.1111/j.1469-8749.2011.03980.xCrossRefGoogle ScholarPubMed
Gringras, P, Gamble, C, Jones, AP, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ. 2012;345:e6664. doi:10.1136/bmj.e6664CrossRefGoogle ScholarPubMed
Gringras, P, Nir, T, Breddy, J, Frydman-Marom, A, Findling, RL. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948–957.e4. doi:10.1016/j.jaac.2017.09.414CrossRefGoogle ScholarPubMed
Maras, A, Schroder, CM, Malow, BA, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018;28(10):699–710. doi:10.1089/cap.2018.0020CrossRefGoogle ScholarPubMed
Malow, BA, Findling, RL, Schroder, CM, et al. Sleep, growth, and puberty after 2 years of prolonged-release melatonin in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2021;60(2):252–261.e3. doi:10.1016/j.jaac.2019.12.007CrossRefGoogle ScholarPubMed
Pranzatelli, MR, Tate, ED, Dukart, WS, Flint, MJ, Hoffman, MT, Oksa, AE. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr. 2005;147(3):372–378. doi:10.1016/j.jpeds.2005.05.016CrossRefGoogle ScholarPubMed
Kem, DL, Posey, DJ, McDougle, CJ. Priapism associated with trazodone in an adolescent with autism. J Am Acad Child Adolesc Psychiatry. 2002;41(7):758. doi:10.1097/00004583-200207000-00004CrossRefGoogle Scholar
Zuddas, A, Di Martino, A, Muglia, P, Cianchetti, C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol. 2000;10(2):79–90. doi:10.1089/cap.2000.10.79CrossRefGoogle ScholarPubMed
First-line treatment for insomnia should not include routine use of antipsychotics, say Canadian psychiatrists - Canadian Psychiatric Association - Association des psychiatres du Canada; https://www.cpa-apc.org/first-line-treatment-for-insomnia-should-not-include-routine-use-of-antipsychotics-say-canadian-psychiatrists/. Accessed January 5, 2022.Google Scholar
Sutcliffe, JS, Delahanty, RJ, Prasad, HC, et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet. 2005;77(2):265–279. doi:10.1086/432648CrossRefGoogle ScholarPubMed
Rai, D, Heuvelman, H, Dalman, C, et al. Association between autism spectrum disorders with or without intellectual disability and depression in young adulthood. JAMA Netw Open. 2018;1(4):e181465. doi:10.1001/jamanetworkopen.2018.1465CrossRefGoogle ScholarPubMed
Nimmo-Smith, V, Heuvelman, H, Dalman, C, et al. Anxiety disorders in adults with autism spectrum disorder: a population-based study. J Autism Dev Disord. 2020;50(1):308–318. doi:10.1007/s10803-019-04234-3CrossRefGoogle ScholarPubMed
Jassi, AD, Vidal-Ribas, P, Krebs, G, Mataix-Cols, D, Monzani, B. Examining clinical correlates, treatment outcomes and mediators in young people with comorbid obsessive-compulsive disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 2021;32(7), 1201–1210. doi:10.1007/s00787-021-01921-4CrossRefGoogle ScholarPubMed
Reddihough, DS, Marraffa, C, Mouti, A, et al. Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA. 2019;322(16):1561–1569. doi:10.1001/jama.2019.14685CrossRefGoogle ScholarPubMed
Reiersen, AM, Handen, B. Commentary on ‘selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).’. Evid-Based Child Health Cochrane Rev J. 2011;6(4):1082–1085. doi:10.1002/ebch.786CrossRefGoogle ScholarPubMed
Posey, DJ, Guenin, KD, Kohn, AE, Swiezy, NB, McDougle, CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001;11(3):267–277. doi:10.1089/10445460152595586CrossRefGoogle ScholarPubMed
McDougle, CJ, Thom, RP, Ravichandran, CT, et al. A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Neuropsychopharmacology. 2022;47(6):1263–1270. doi:10.1038/s41386-022-01295-4CrossRefGoogle ScholarPubMed
Realmuto, GM, August, GJ, Garfinkel, BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9(2):122–125. doi:10.1097/00004714-198904000-00009CrossRefGoogle ScholarPubMed
McCormick, LH. Treatment with buspirone in a patient with autism. Arch Fam Med. 1997;6(4):368–370. doi:10.1001/archfami.6.4.368CrossRefGoogle Scholar
Ceranoglu, TA, Wozniak, J, Fried, R, et al. A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder. J Child Adolesc Psychopharmacol. 2019;29(1):28–33. doi:10.1089/cap.2018.0021CrossRefGoogle ScholarPubMed
Chugani, DC, Chugani, HT, Wiznitzer, M, et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. J Pediatr. 2016;170:45–53.e1-4. doi:10.1016/j.jpeds.2015.11.033CrossRefGoogle ScholarPubMed
Ghanizadeh, A, Ayoobzadehshirazi, A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatr Neurol. 2015;52(1):77–81. doi:10.1016/j.pediatrneurol.2014.09.017CrossRefGoogle ScholarPubMed
Howes, OD, Rogdaki, M, Findon, JL, et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for psychopharmacology. J Psychopharmacol. 2018;32(1):3–29. doi:10.1177/0269881117741766CrossRefGoogle ScholarPubMed
Koomar, T, Thomas, TR, Pottschmidt, NR, Lutter, M, Michaelson, JJ. Estimating the prevalence and genetic risk mechanisms of ARFID in a large autism cohort. Front Psychiatry. 2021;12:668297. doi:10.3389/fpsyt.2021.668297CrossRefGoogle Scholar
Bourne, L, Mandy, W, Bryant-Waugh, R. Avoidant/restrictive food intake disorder and severe food selectivity in children and young people with autism: a scoping review. Dev Med Child Neurol. 2022;64(6):691–700. doi:10.1111/dmcn.15139CrossRefGoogle Scholar
Sharp, WG, Berry, RC, McCracken, C, et al. Feeding problems and nutrient intake in children with autism spectrum disorders: a meta-analysis and comprehensive review of the literature. J Autism Dev Disord. 2013;43(9):2159–2173. doi:10.1007/s10803-013-1771-5CrossRefGoogle ScholarPubMed
Burton, C, Allan, E, Eckhardt, S, et al. Case presentations combining family-based treatment with the unified protocols for transdiagnostic treatment of emotional disorders in children and adolescents for comorbid avoidant restrictive food intake disorder and autism spectrum disorder. J Can Acad Child Adolesc Psychiatry. 2021;30(4):280–291.Google ScholarPubMed
Brigham, KS, Manzo, LD, Eddy, KT, Thomas, JJ. Evaluation and treatment of avoidant/restrictive food intake disorder (ARFID) in adolescents. Curr Pediatr Rep. 2018;6(2):107–113. doi:10.1007/s40124-018-0162-yCrossRefGoogle ScholarPubMed
Salazar de Pablo, G, Pastor Jordá, C, Vaquerizo-Serrano, J, et al. Systematic review and meta-analysis: efficacy of pharmacological interventions for irritability and emotional dysregulation in autism spectrum disorder and predictors of response. J Am Acad Child Adolesc Psychiatry. 2023;62(2):151–168. doi:10.1016/j.jaac.2022.03.033CrossRefGoogle ScholarPubMed
Sultan, RS, Correll, CU, Zohar, J, Zalsman, G, Veenstra-VanderWeele, J. What’s in a Name? Moving to neuroscience-based nomenclature in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2018;57(10):719–721. doi:10.1016/j.jaac.2018.05.024CrossRefGoogle Scholar
McPheeters, ML, Warren, Z, Sathe, N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1312–e1321. doi:10.1542/peds.2011-0427CrossRefGoogle ScholarPubMed
Wilens, TE, Bukstein, O, Brams, M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.e2. doi:10.1016/j.jaac.2011.10.012CrossRefGoogle ScholarPubMed
Kollins, SH, Jain, R, Brams, M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–e1413. doi:10.1542/peds.2010-1260CrossRefGoogle ScholarPubMed
Aman, MG, Bukstein, OG, Gadow, KD, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014;53(1):47–60.e1. doi:10.1016/j.jaac.2013.09.022CrossRefGoogle ScholarPubMed
De Giorgi, R, De Crescenzo, F, D’Alò, GL, et al. Prevalence of non-affective psychoses in individuals with autism spectrum disorders: a systematic review. J Clin Med. 2019;8(9):1304. doi:10.3390/jcm8091304CrossRefGoogle ScholarPubMed
Bakken, TL, Friis, S, Lovoll, S, Smeby, NA, Martinsen, H. Behavioral disorganization as an indicator of psychosis in adults with intellectual disability and autism. Ment Health Asp Dev Disabil. 2007;10(2):37–47.Google Scholar
Foss-Feig, JH, Velthorst, E, Smith, L, et al. Clinical profiles and conversion rates among young individuals with autism spectrum disorder who present to clinical high risk for psychosis services. J Am Acad Child Adolesc Psychiatry. 2019;58(6):582–588. doi:10.1016/j.jaac.2018.09.446CrossRefGoogle ScholarPubMed
Saitow, F, Takumi, T, Suzuki, H. Change in serotonergic modulation contributes to the synaptic imbalance of neuronal circuit at the prefrontal cortex in the 15q11-13 duplication mouse model of autism. Neuropharmacology. 2020;165:107931. doi:10.1016/j.neuropharm.2019.107931CrossRefGoogle Scholar
Sugie, Y, Sugie, H, Fukuda, T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005;35(3):377–385. doi:10.1007/s10803-005-3305-2CrossRefGoogle Scholar
Najjar, F, Owley, T, Mosconi, MW, et al. Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism. J Child Adolesc Psychopharmacol. 2015;25(6):467–474. doi:10.1089/cap.2014.0158CrossRefGoogle ScholarPubMed
Owley, T, Brune, CW, Salt, J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010;3(1):1–7. doi:10.1002/aur.109CrossRefGoogle ScholarPubMed
King, BH. Fluoxetine and repetitive behaviors in children and adolescents with autism spectrum disorder. JAMA. 2019;322(16):1557–1558. doi:10.1001/jama.2019.11738CrossRefGoogle ScholarPubMed
Luft, MJ, Lamy, M, DelBello, MP, McNamara, RK, Strawn, JR. Antidepressant-induced activation in children and adolescents: risk, recognition and management. Curr Probl Pediatr Adolesc Health Care. 2018;48(2):50–62. doi:10.1016/j.cppeds.2017.12.001CrossRefGoogle Scholar
Lambe, EK, Fillman, SG, Webster, MJ, Shannon Weickert, C. Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development. PloS One. 2011;6(7):e22799. doi:10.1371/journal.pone.0022799CrossRefGoogle ScholarPubMed
Gupta, M, Gupta, N. FDA black box warning for SSRI: reexamining the role of high-functioning autism as a confounder. Adv Neurodev Disord. 2022;26. doi:10.1007/s41252-022-00301-6Google Scholar
de Silva, VA, Suraweera, C, Ratnatunga, SS, Dayabandara, M, Wanniarachchi, N, Hanwella, R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341. doi:10.1186/s12888-016-1049-5CrossRefGoogle ScholarPubMed
Wang, L, Cai, Y, Fan, X. Metformin administration during early postnatal life rescues autistic-like behaviors in the BTBR T+ Itpr3tf/J mouse model of autism. Front Behav Neurosci. 2018;12:290. doi:10.3389/fnbeh.2018.00290CrossRefGoogle ScholarPubMed
Campbell, JM, Stephenson, MD, de Courten, B, Chapman, I, Bellman, SM, Aromataris, E. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J Alzheimers Dis. 2018;65(4):1225–1236. doi:10.3233/JAD-180263CrossRefGoogle ScholarPubMed
Aman, MG, Hollway, JA, Veenstra-VanderWeele, J, et al. Effects of metformin on spatial and verbal memory in children with ASD and overweight associated with atypical antipsychotic use. J Child Adolesc Psychopharmacol. 2018;28(4):266–273. doi:10.1089/cap.2017.0072CrossRefGoogle ScholarPubMed
Protic, D, Aydin, EY, Tassone, F, Tan, MM, Hagerman, RJ, Schneider, A. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. Mol Genet Genomic Med. 2019;7(7):e00745. doi:10.1002/mgg3.745CrossRefGoogle ScholarPubMed
University of California, Davis. A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals with Fragile X Syndrome. clinicaltrials.gov; 2022; https://clinicaltrials.gov/ct2/show/NCT03479476. Accessed March 13, 2022.Google Scholar
Beversdorf, DQ, Carpenter, AL, Miller, RF, Cios, JS, Hillier, A. Effect of propranolol on verbal problem solving in autism spectrum disorder. Neurocase. 2008;14(4):378–383. doi:10.1080/13554790802368661CrossRefGoogle ScholarPubMed
Narayanan, A, White, CA, Saklayen, S, et al. Effect of propranolol on functional connectivity in autism spectrum disorder--a pilot study. Brain Imaging Behav. 2010;4(2):189–197. doi:10.1007/s11682-010-9098-8CrossRefGoogle ScholarPubMed
Beversdorf, DQ, Saklayen, S, Higgins, KF, Bodner, KE, Kanne, SM, Christ, SE. Effect of propranolol on word fluency in autism. Cogn Behav Neurol. 2011;24(1):11–17. doi:10.1097/WNN.0b013e318204d20eCrossRefGoogle ScholarPubMed
Bodner, KE, Beversdorf, DQ, Saklayen, SS, Christ, SE. Noradrenergic moderation of working memory impairments in adults with autism spectrum disorder. J Int Neuropsychol Soc. 2012;18(3):556–564. doi:10.1017/S1355617712000070CrossRefGoogle ScholarPubMed
Zamzow, RM, Christ, SE, Saklayen, SS, et al. Effect of propranolol on facial scanning in autism spectrum disorder: a preliminary investigation. J Clin Exp Neuropsychol. 2014;36(4):431–445. doi:10.1080/13803395.2014.904844CrossRefGoogle ScholarPubMed
Zamzow, RM, Ferguson, BJ, Stichter, JP, et al. Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study. Psychopharmacology. 2016;233(7):1171–1178. doi:10.1007/s00213-015-4199-0CrossRefGoogle ScholarPubMed
Zamzow, RM, Ferguson, BJ, Ragsdale, AS, Lewis, ML, Beversdorf, DQ. Effects of acute beta-adrenergic antagonism on verbal problem solving in autism spectrum disorder and exploration of treatment response markers. J Clin Exp Neuropsychol. 2017;39(6):596–606. doi:10.1080/13803395.2016.1252724CrossRefGoogle ScholarPubMed
Hegarty, JP, Ferguson, BJ, Zamzow, RM, et al. Beta-adrenergic antagonism modulates functional connectivity in the default mode network of individuals with and without autism spectrum disorder. Brain Imaging Behav. 2017;11(5):1278–1289. doi:10.1007/s11682-016-9604-8CrossRefGoogle ScholarPubMed
London, EB, Yoo, JH, Fethke, ED, Zimmerman-Bier, B. The safety and effectiveness of high-dose propranolol as a treatment for challenging behaviors in individuals with autism spectrum disorders. J Clin Psychopharmacol. 2020;40(2):122–129. doi:10.1097/JCP.0000000000001175CrossRefGoogle ScholarPubMed
Riikonen, R. Treatment of autistic spectrum disorder with insulin-like growth factors. Eur J Paediatr Neurol. 2016;20(6):816–823. doi:10.1016/j.ejpn.2016.08.005CrossRefGoogle ScholarPubMed
John, S, Jaeggi, AV. Oxytocin levels tend to be lower in autistic children: a meta-analysis of 31 studies. Autism Int J Res Pract. 2021;25(8):2152–2161. doi:10.1177/13623613211034375CrossRefGoogle ScholarPubMed
Minakova, E, Lang, J, Medel-Matus, JS, et al. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PloS One. 2019;14(1):e0210389. doi:10.1371/journal.pone.0210389CrossRefGoogle Scholar
Horvath, A, Łukasik, J, Szajewska, H. ω-3 fatty acid supplementation does not affect autism spectrum disorder in children: a systematic review and meta-analysis. J Nutr. 2017;147(3):367–376. doi:10.3945/jn.116.242354CrossRefGoogle Scholar
Demarquoy, C, Demarquoy, J. Autism and carnitine: a possible link. World J Biol Chem. 2019;10(1):7–16. doi:10.4331/wjbc.v10.i1.7CrossRefGoogle ScholarPubMed
Malaguarnera, M, Cauli, O. Effects of l-carnitine in patients with autism spectrum disorders: review of clinical studies. Mol. 2019;24(23):E4262. doi:10.3390/molecules24234262CrossRefGoogle ScholarPubMed
Naviaux, RK, Curtis, B, Li, K, et al. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. 2017;4(7):491–505. doi:10.1002/acn3.424CrossRefGoogle ScholarPubMed
Dean, OM, Gray, KM, Villagonzalo, KA, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. 2017;51(3):241–249. doi:10.1177/0004867416652735CrossRefGoogle ScholarPubMed
Millward, C, Ferriter, M, Calver, SJ, Connell‐Jones, GG. Gluten‐ and casein‐free diets for autistic spectrum disorder. Cochrane Database Syst Rev. 2008;CD003498. doi:10.1002/14651858.CD003498.pub3Google ScholarPubMed
Piwowarczyk, A, Horvath, A, Łukasik, J, Pisula, E, Szajewska, H. Gluten- and casein-free diet and autism spectrum disorders in children: a systematic review. Eur J Nutr. 2018;57(2):433–440. doi:10.1007/s00394-017-1483-2CrossRefGoogle ScholarPubMed
Quan, L, Xu, X, Cui, Y, et al. A systematic review and meta-analysis of the benefits of a gluten-free diet and/or casein-free diet for children with autism spectrum disorder. Nutr Rev. 2021;7:nuab073. doi:10.1093/nutrit/nuab073Google Scholar
McGuinness, G, Kim, Y. Sulforaphane treatment for autism spectrum disorder: a systematic review. EXCLI J. 2020;19:892–903. doi:10.17179/excli2020-2487Google ScholarPubMed
Hellings, JA, Reed, G, Cain, SE, et al. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. J Child Adolesc Psychopharmacol. 2015;25(2):150–159. doi:10.1089/cap.2014.0003CrossRefGoogle ScholarPubMed
Li, Z, Ichikawa, J, Meltzer, HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology. 2003;167(3):315–323. doi:10.1007/s00213-003-1418-xCrossRefGoogle ScholarPubMed
Bhatti, I, Thome, A, Smith, PO, et al. A retrospective study of amitriptyline in youth with autism spectrum disorders. J Autism Dev Disord. 2013;43(5):1017–1027. doi:10.1007/s10803-012-1647-0CrossRefGoogle ScholarPubMed
Hellings, JA, Arnold, LE, Han, JC. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline. Expert Opin Pharmacother. 2017;18(6):581–588. doi:10.1080/14656566.2017.1308483CrossRefGoogle ScholarPubMed
Chez, MG, Burton, Q, Dowling, T, Chang, M, Khanna, P, Kramer, C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574–579. doi:10.1177/0883073807302611CrossRefGoogle ScholarPubMed
Ghaleiha, A, Asadabadi, M, Mohammadi, MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2013;16(4):783–789. doi:10.1017/S1461145712000880CrossRefGoogle ScholarPubMed
Aman, MG, Findling, RL, Hardan, AY, et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. J Child Adolesc Psychopharmacol. 2017;27(5):403–412. doi:10.1089/cap.2015.0146CrossRefGoogle ScholarPubMed
Hardan, AY, Hendren, RL, Aman, MG, et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism Int J Res Pract. 2019;23(8):2096–2111. doi:10.1177/1362361318824103CrossRefGoogle ScholarPubMed
Joshi, G, Wozniak, J, Faraone, SV, et al. A prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder. J Clin Psychopharmacol. 2016;36(3):262–271. doi:10.1097/JCP.0000000000000499CrossRefGoogle ScholarPubMed
Soorya, LV, Fogg, L, Ocampo, E, et al. Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2021;31(7):475–484. doi:10.1089/cap.2021.0010CrossRefGoogle ScholarPubMed
King, BH, Wright, DM, Handen, BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658–665. doi:10.1097/00004583-200106000-00010CrossRefGoogle ScholarPubMed
Mohammadi, MR, Yadegari, N, Hassanzadeh, E, et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clin Neuropharmacol. 2013;36(6):179–184. doi:10.1097/WNF.0b013e3182a9339dCrossRefGoogle ScholarPubMed
Morrow, K, Choi, S, Young, K, Haidar, M, Boduch, C, Bourgeois, JA. Amantadine for the treatment of childhood and adolescent psychiatric symptoms. Proc Bayl Univ Med Cent. 34(5):566–570. doi:10.1080/08998280.2021.1925827CrossRefGoogle Scholar